Tech Company Financing Transactions
Carisma Therapeutics Funding Round
Symbiosis, AbbVie Biotech Ventures and Agent Capital participated in a $47 million Series B funding round for Carisma Therapeutics. The round was announced on 1/11/2021.
Transaction Overview
Company Name
Announced On
1/11/2021
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series B
Investors
Proceeds Purpose
The funding will allow CARISMA to further develop its proprietary engineered-macrophage platform, continue pipeline expansion in cancer indications and enable the platform's application to disease areas outside of cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3675 Market St. 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Overview
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Kelly
Chief Medical Officer
Debora Barton
Chief Technical Officer
Daniel Cushing
VP - Bus. Development
Thomas Wilton
VP - R & D
Michael Klichinsky
Browse more venture capital transactions:
Prev: 1/11/2021: IsoPlexis venture capital transaction
Next: 1/11/2021: MCI Onehealth Technologies venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs